combretastatin A1 di-phosphate (OXi4503) / Oncotelic  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
combretastatin A1 di-phosphate (OXi4503) / Oncotelic
NCT00977210: Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Completed
1
40
Europe
OXi4503
Mateon Therapeutics, Cancer Research UK
Solid Tumors
09/10
 
NCT01085656: A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

Terminated
1
18
US
OXi4503, Combretastatin A1 Diphosphate, CA1P
University of Florida, The Leukemia and Lymphoma Society
Leukemia, Myelogenous, Acute, Myelodysplastic Syndromes
01/16
01/16

Download Options